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ABSTRACT
Objective To investigate whether calcium supplements
increase the risk of cardiovascular events.
Design Patient level and trial level meta-analyses.
Data sources Medline, Embase, and Cochrane Central
Register of Controlled Trials (1966-March 2010),
reference lists of meta-analyses of calcium supplements,
and two clinical trial registries. Initial searches were
carried out in November 2007, with electronic database
searches repeated in March 2010.
Study selection Eligible studies were randomised,
placebo controlled trials of calcium supplements
(≥500 mg/day), with 100 or more participants of mean
age more than 40 years and study duration more than one
year. The lead authors of eligible trials supplied data.
Cardiovascular outcomes were obtained from self reports,
hospital admissions, and death certificates.
Results 15 trials were eligible for inclusion, five with
patient level data (8151 participants, median follow-up
3.6 years, interquartile range 2.7-4.3 years) and 11 with
trial level data (11 921 participants, mean duration
4.0 years). In the five studies contributing patient level
data, 143 people allocated to calcium had a myocardial
infarction compared with 111 allocated to placebo
(hazard ratio 1.31, 95% confidence interval 1.02 to 1.67,
P=0.035). Non-significant increases occurred in the
incidence of stroke (1.20, 0.96 to 1.50, P=0.11), the
composite end point of myocardial infarction, stroke, or
sudden death (1.18, 1.00 to 1.39, P=0.057), and death
(1.09, 0.96 to 1.23, P=0.18). The meta-analysis of trial
level data showed similar results: 296 people had a
myocardial infarction (166 allocated to calcium, 130 to
placebo), with an increased incidence of myocardial
infarction in those allocated to calcium (pooled relative
risk 1.27, 95% confidence interval 1.01 to 1.59,
P=0.038).
Conclusions Calcium supplements (without
coadministered vitamin D) are associated with an
increased risk of myocardial infarction. As calcium
supplements are widely used these modest increases in
risk of cardiovascular disease might translate into a large
burden of disease in the population. A reassessment of
the role of calcium supplements in the management of
osteoporosis is warranted.

INTRODUCTION

Osteoporosis is a major cause of morbidity and mortality in older people.1 Calcium supplements marginally reduce the risk of fracture,2 3 and most guidelines
recommend adequate calcium intake as an integral
part of the prevention or treatment of osteoporosis.4 5
Consequently, calcium supplements are commonly
used by people over the age of 50. Observational studies suggest that high calcium intake might protect
against vascular disease,6-8 and the findings are consistent with those of interventional studies of calcium supplements that show improvement in some vascular risk
factors.9-11 In contrast, calcium supplements accelerate
vascular calcification and increase mortality in patients
with renal failure, in both dialysis and predialysis
populations.12-14 Furthermore, a five year randomised
controlled trial of calcium supplements in healthy
older women, in which cardiovascular events were
prespecified as secondary end points, recently
reported possible increases in rates of myocardial
infarction and cardiovascular events in women allocated to calcium.15 16 We carried out a meta-analysis
of cardiovascular events in randomised trials of calcium supplements.
METHODS

In November 2007 we searched Medline, Embase, and
the Cochrane Central Register of Controlled Trials for
randomised placebo controlled trials of calcium supplements, using the terms “calcium”, “randomised
controlled trial”, and “placebo” as text words, and corresponding MeSH terms (full details are available from
the authors). We searched for studies in the reference
lists of meta-analyses published between 1990 and
2007 of the effect of calcium supplements on bone density, fracture, colorectal neoplasia, and blood pressure,
and in two clinical trial registries (ClinicalTrials.gov
and Australian New Zealand Clinical Trials Registry).
No language restrictions were applied. In March 2010
we updated the searches of the electronic databases
(Medline: January 1966-March 2010, Embase: January 1980-March 2010, Central Register of Controlled
Trials: first quarter 2010).
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Study selection
We included studies if they were randomised, double
blind, placebo controlled trials; elemental calcium was
administered at a dose of ≥500 mg/day; the participants’ mean age at baseline was more than 40 years;
100 or more participants were randomised; participants of either sex were studied; and the trial duration
was more than one year.
We excluded trials concerning calcium and vitamin
D given together with a placebo comparator (trials
were only eligible if vitamin D was given to both intervention and control groups, because vitamin D supplementation has been associated with decreased
mortality17); trials in which calcium was administered
in the form of dietary modification or a complex nutritional supplement; and trials in which most participants had a major systemic disease other than
osteoporosis.
Search results
One investigator (MB) carried out the initial search and
two investigators (AG and MB) independently
reviewed all potentially relevant studies. Overall, 190
potentially relevant reports of studies were identified
from the initial searches, but only 15 studies were eligible for analysis.15 16 18-33 Thirteen studies compared
calcium supplements with placebo,15 16 18-27 29 31-33 one
study had a 2×2 factorial design allowing comparison
of calcium with placebo and calcium plus vitamin D
with vitamin D,28 and one study compared calcium
plus alendronate with alendronate.30
Data description
We invited the lead author of each eligible study to
provide patient level data on cardiovascular events
that occurred during the study irrespective of whether
the participant was still taking the trial drug. When
such data were not available we requested summary
data at trial level. We obtained patient level data on
cardiovascular outcomes for five studies, and partially
complete trial level data for six. No data were available
for four studies because the original records were no
longer available and cardiovascular events were not

Reports of studies identified by initial search (n=11 363)
Reports of potentially relevant studies
identified and screened for retrieval (n=190)
Reports of studies excluded (n=162):
Study size (n=111)
Duration ≤12 months (n=30)
Study design (n=21)
28 reports of 15 studies eligible for inclusion

Fig 1 | Flowchart of studies. Initial search was in November
2007: 9358 reports were identified, 173 reports of potentially
relevant studies retrieved, 150 reports excluded, and 23
reports of 15 individual studies identified. Search was
updated in March 2010: a further 2005 reports were identified
and 17 reports retrieved but no new studies identified
page 2 of 9

previously reported,18 20 or no cardiovascular data
were available.23 26 Thus, patient level data on cardiovascular outcomes were available for 63% of participants in the 15 eligible studies, complete trial level
data for 85% of participants, and at least partially complete trial level data for 93% of participants. Basic
demographic and other trial related data were either
supplied by the lead authors (or nominated deputies)
or extracted from the original publication by an investigator (MB).
Ascertainment of cardiovascular events
We considered a myocardial infarction to have
occurred when either of the terms “myocardial infarction” or “heart attack”, or code 410 (international classification of diseases, ninth revision), was used to
describe the event. A stroke was considered to have
occurred when any of the terms “stroke”, “cerebral
infarction”, “intracerebral hemorrhage”, “subarachnoid hemorrhage”, or “cerebrovascular accident”, or
any of the ICD-9 codes 430, 431, 433, 434 were used
to describe the event. We considered a sudden death to
have occurred when the term “sudden death” or the
ICD-9 code 798 was used to describe the event.
Five studies contributed patient level data on cardiovascular events. For one study,21 22 self reports of unadjudicated events were supplied. Another study28
supplied self reports of hospital admissions and cause
of death from death certificates. Each event was then
independently adjudicated by two physicians blinded
to the treatment allocation of the participants (MB,
AG), and any disagreements were resolved by consensus. For another study,25 verified events from hospital
discharge data were supplied along with causes of
deaths from death certificates. The causes of death
were again independently adjudicated. For two
studies,15 33 data from self reports, hospital admissions,
and death certificates were independently adjudicated
by a cardiologist or neurologist, as previously
described.16 For six studies contributing trial level
data, all data on cardiovascular events were supplied
by the lead authors and were obtained from physician
reported cause of death in one study27 and a combination of self reports and hospital discharge data in five
studies.19 24 29-32
End points
The prespecified primary end points were time to first
myocardial infarction, time to first stroke, and time to
first event for the composite end point of myocardial
infarction, stroke, or sudden death. The secondary end
point was time to death (all cause mortality).
Statistical analysis
In trials with patient level data, we analysed each end
point using a Cox proportional hazards model, with a
dummy coded variable representing each study in the
model, and we reported the hazard ratio, with 95%
confidence interval, and number needed to treat. The
assumption of proportional hazards was explored by
BMJ | ONLINE FIRST | bmj.com
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Table 1 | Characteristics of 15 studies eligible for inclusion in meta-analysis
No in calcium group/
No in control group

Studies

Daily dose
and supplement type

Trial duration
(years)

Primary end point

Baseline mean
age (years)

% female

100

Patient level data on cardiovascular outcomes:
Reid 199321 22

68/67

Baron 199925

464/466

Grant 200528

2617/2675

1 g lactogluconate-carbonate

4

Bone mineral density

58

1.2 g carbonate

4

Colorectal adenoma

61

28

1 g carbonate

4*

Low trauma fracture

77

85
100

Reid 200615 16

732/739

1 g citrate

5

Clinical fracture

74

Reid 200833

216/107

0.6 g or 1.2 g citrate

2

Spine bone mineral density

56

0

4.1

—

73

78

Subtotal/average†

4097/4054

—

Trial level data on cardiovascular outcomes‡:
Dawson-Hughes 199019

238/123

0.5 g carbonate or citrate

2

Spine bone mineral density

58

100

Riggs 199824

119/117

1.6 g citrate

4

Bone mineral density

66

100

Bonithon-Kopp 200027

204/212

2 g lactogluconate-carbonate

3

Colorectal adenoma

59

37

Prince 200629

730/730

1.2 g carbonate

5

Osteoporotic fracture

75

100

Bonnick 200730

282/281

1 g carbonate

2

Spine bone mineral density

66

100

Lappe 200731 32

446/288

1.4 g citrate or 1.5 g carbonate

4

Fracture incidence

67

100

Subtotal/average†

2019/1751

Total/average†

6116/5805

—

—

3.8
4.0

68

93

72

83

No data on cardiovascular outcomes:
Smith 198918§

84/85

1.5 g carbonate

4

Arm bone mineral density

51

100

Elders 199120

198/97

1g or 2g lactogluconate-carbonate
or citrate

2

Spine bone mineral density

NA

100

Recker 199623

95/102

1.2 g carbonate

4

Vertebral fracture

74

100

Peacock 200026

126/135

0.75 g citrate

4

Hip bone mineral density

76

72

Subtotal/average†

503/419

—

69

88

NA=not available.
*All participants were followed for two years with a median follow-up of 45 months.
†Weighted by person years of follow-up.
‡Complete trial level data were available for two studies.29 31 Partially complete data were available for four studies19
§No original records remained but lead author recalled no heart attacks in either treatment group.

carrying out a test for proportionality of the interaction
between variables included in the model and the logarithm of time. For a small number of events (<10%) the
timing was unknown. We treated these events as if they
had occurred on the last day of follow-up for that participant. Possible confounding by covariates was
assessed by repeating these models including prespecified covariates likely to be associated with cardiovascular outcomes (age, sex, smoking status, presence
of diabetes, dyslipidaemia, and hypertension at baseline, and history of coronary heart disease) where data
were available for more than 80% of participants. Prespecified subgroup analyses for dietary calcium, age,
sex, vitamin D status (serum 25-hydroxyvitamin D
≥50 nmol/l or <50 nmol/l), and supplement type
were done using interaction terms between treatment
allocation and the factor of interest.
We used Poisson regression models to assess the
relation between the total number of events and treatment allocation. Because recurrent cardiovascular
events in an individual are unlikely to be independent,
we used Poisson regression with general estimating
equations to account for the intra-individual dependence of events.
To assess statistical heterogeneity between summary
data at trial level we used Cochran’s Q statistic
(P<0.10) and the I2 statistic (I2>50%). No significant
statistical heterogeneity existed between trials in any
BMJ | ONLINE FIRST | bmj.com

—

4.0

24 27 30

(see table 2 for details).

of the analyses. We used random effects models to
pool summary data at trial level. Publication bias was
assessed using Funnel plots and Egger’s regression
model.34 Analyses were done using SAS version 9.1
or Comprehensive Meta-analysis version 2 (Biostat,
Englewood, NJ). All tests were two tailed and we considered P<0.05 as significant.
RESULTS
Figure 1 shows the results of the literature search and
table 1 the characteristics of the eligible studies. The
quality of the five studies contributing patient level
data has been independently assessed in previous systematic reviews. 3 35 36
All 11 eligible trials were double blind, randomised
studies. The method of randomisation was stated explicitly in seven: one used a central randomisation service
and six used computer generated random numbers.
Allocation concealment was explicitly described in
four studies. Ten studies gave details of participants
who withdrew or were lost to follow-up. Compliance
was reported in all 11 studies, but the definitions for
compliance differed between studies and were not
always comparable. In general, studies reported compliance of more than 75% in participants who were taking tablets at study completion. Table 2 shows the
baseline cardiovascular characteristics, dietary calcium intake, and vitamin D status of participants.
page 3 of 9
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Table 2 | Baseline cardiovascular and other variables in trials with patient or trial level data available for cardiovascular outcomes. Values are means
(standard deviations) unless stated otherwise
Studies

Dietary calcium
(mg/day)

Vitamin D*
(nmol/l)

Weight
(kg)

Current smoker
(%)

Hypertension
(%)

Diabetes
(%)

Ischaemic heart
disease (%)

Lipid disorder
(%)
NA

Dawson-Hughes19

406 (84)

NA

NA

NA

NA

NA

NA

Reid21 22

750 (290)

93 (37)

65 (9)

10

9

0

2

1

Riggs24

710 (290)

80 (25)

NA

NA

NA

NA

NA

NA

Baron25

880 (440)

73 (27)

82 (15)

19

37

10

12

32

Bonithon-Kopp27

980 (380)

NA

NA

NA

NA

NA

NA

NA

Grant28

820 (350)

45 (18)†

65 (13)

12

NA

8

NA

NA

Reid15 16

860 (390)

54 (18)

67 (11)

3

29

3

8

8

Prince29

915

NA

69 (13)

NA

NA

NA

NA

NA

Bonnick30

1240 (580)

NA

NA

0.4

NA

NA

NA

NA

Lappe31 32

1070

72 (20)

77 (15)

NA

NA

NA

NA

NA

870 (450)

92 (33)

83 (12)

3

8

0.3

0.3

4

Reid33

NA=not available.
*25-hydroxyvitamin D.
†25-hydroxyvitamin D measured in sample of 80 participants.

Cardiovascular events by treatment allocation are
shown in table 3.
Patient level analysis
Table 4 shows the baseline characteristics of the treatment groups in the five studies contributing patient
level data. The median (interquartile range) duration
of follow-up in both groups was 3.6 (2.7-4.3) years.
In total, 143 people allocated to calcium had a myocardial infarction during follow-up compared with 111
allocated to placebo. The risk of incident myocardial
infarction in those allocated to calcium increased by
31% (hazard ratio 1.31, 95% confidence interval 1.02
to 1.67, P=0.035. fig 2). During follow-up, 167 people
allocated to calcium and 143 allocated to placebo had a
stroke (1.20, 0.96 to 1.50, P=0.11), 293 people allocated to calcium and 254 allocated to placebo had
any of myocardial infarction, stroke, or sudden death
(1.18, 1.00 to 1.39, P=0.057), and 519 people allocated
to calcium and 487 allocated to placebo died (1.09,
0.96 to 1.23, P=0.18). The number needed to treat
(NNT) with calcium for five years to cause one incident
event was 69 for myocardial infarction, 100 for stroke,
61 for any of myocardial infarction, stroke, or sudden
death, and 77 for death. Adjusting for prespecified covariates related to cardiovascular outcomes with data
available for more than 80% of participants (age, sex,
smoking status, and diabetes) did not change the results
of the primary analyses.
Prespecified subgroup analyses showed a significant
interaction between treatment allocation and dietary
calcium intake for myocardial infarction. Calcium
treatment was associated with an increased risk of myocardial infarction in people with dietary calcium intake
above the median of 805 mg/day (hazard ratio 1.85,
95% confidence interval 1.28 to 2.67) but no increased
risk in those with dietary calcium intake below the
median (0.98, 0.69 to 1.38, P for interaction 0.01).
When the cohort was divided by fifths of dietary calcium intake rounded to the nearest 100 mg/day, the
respective hazard ratios (95% confidence intervals)
page 4 of 9

for the effect of calcium treatment on myocardial
infarction were 1.18 (0.70 to 2.00) for <500 mg/day,
0.68 (0.39 to 1.18) for 500-699 mg/day, 2.28 (1.26 to
4.15) for 700-899 mg/day, 1.81 (0.97 to 3.41) for 9001099 mg/day, and 1.41 (0.81 to 2.48) for ≥1100 mg/
day; test for linear trend when hazard ratios are
expressed relative to the <500 mg/d fifth, P=0.12.
Interactions between treatment allocation and age,
sex, vitamin D status, or supplement type for myocardial infarction were not significant, nor were they
between treatment allocation and any of these variables or dietary calcium intake for stroke, the composite end point, or death.
Recurrent cardiovascular events tended to be more
common in people allocated to calcium. Comparing
people allocated to calcium with those allocated to placebo, 19 versus 13 had more than one myocardial
infarction (P=0.38), 21 versus 13 had more than one
stroke (P=0.23), and 59 versus 32 had more than one
of myocardial infarction, stroke, or sudden death
(P=0.006). Poisson regression models with general estimating equations were used to estimate the effect of
calcium on the total number of events, including incident and recurrent events. Overall, 164 myocardial
infarctions occurred in people allocated to calcium
compared with 125 in those allocated to placebo (relative risk 1.32, 95% confidence interval 1.02 to 1.71,
P=0.032). Stroke occurred in 190 people allocated to
calcium compared with 156 allocated to placebo (1.24,
0.99 to 1.56, P=0.07). In total, 361 myocardial infarctions, strokes, or sudden deaths occurred in people
allocated to calcium compared with 287 in people allocated to calcium (1.27, 1.07 to 1.51, P=0.006).
Trial level analysis
Table 3 shows summary data on cardiovascular events
at trial level. Eight studies15 16 21 22 25 28-33 were included
in the main analysis. A further three trials19 24 27 had
data only available for subgroups of participants.
These three trials were included in a sensitivity analysis
that included data from all 11 trials. Publication bias
BMJ | ONLINE FIRST | bmj.com
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Table 3 | Number of people with cardiovascular events and deaths by treatment allocation
Calcium group

Placebo group

No of
participants

Myocardial
infarction

Stroke

Composite*

Dawson-Hughes19†

238

0

0

NA

Reid21 22

68

0

2

Riggs24‡

119

0

Baron25

464

20

Studies

Death

No of
participants

Myocardial
infarction

Stroke

Composite*

Death

NA

123

0

1

NA

NA

2

0

67

0

1

1

0

0

0

1

117

0

0

0

0

15

31

25

466

17

11

28

22

Bonithon-Kopp27§

204

0

1

1

8

212

0

0

1

9

Grant28¶

1311

45

56

97

238

1332

39

48

86

217

Grant28**

1306

44

60

100

220

1343

34

58

89

218

Reid15 16

732

31

34

60

34

739

21

25

50

29

Prince29††

730

21

38

56

29

730

17

40

56

38

Bonnick30‡‡

282

0

1

NA

2

281

0

2

NA

1

Lappe31 32††

446

2

5

8

NA

288

2

4

8

NA

Reid33

216

3

0

3

2

107

0

0

0

1

Total

6116

166

212

358

559

5805

130

190

319

535

NA=not available.
*Any of myocardial infarction, stroke, or sudden death. Seventeen events were classified as sudden deaths that occurred in eight people allocated to calcium and nine allocated to placebo.
†Unpublished trial level data provided by author. Data on stroke available only for participants who withdrew from study.
‡Unpublished trial level data provided by author. Data available only for participants who withdrew from study.
§Unpublished trial level data provided by author. Data on cause of death only.
¶Calcium versus placebo arms in Randomised Evaluation of Calcium or Vitamin D (RECORD) study.
**Calcium and vitamin D versus placebo plus vitamin D arms in Randomised Evaluation of Calcium or Vitamin D (RECORD) study.
††Unpublished trial level data provided by author.
‡‡Unpublished trial level data provided by Boyd Scott.

was not evident on inspection of Funnel plots or in
Egger’s regression model in any analysis (P>0.40 for
all analyses). Figure 3 shows the results of the main
analysis. Allocation to calcium supplements was associated with an increased risk of myocardial infarction
(relative risk 1.27, 95% confidence interval 1.01 to
1.59, P=0.038) but not stroke, the composite end
point, or death. Including data from the three additional studies in the sensitivity analysis did not significantly change the results for any end point.
DISCUSSION
In this pooled analysis of around 12 000 participants
from 11 randomised controlled trials, calcium supplements were associated with about a 30% increase in the
incidence of myocardial infarction and smaller, nonsignificant, increases in the risk of stroke and mortality.
When recurrent events in 10-17% of participants were
included in analyses, the results were similar, although
the relative risks tended to be slightly larger. The findings were consistent across trials, with an increased
relative risk of myocardial infarction with calcium
observed in six of the seven trials in which at least
one event occurred, although no individual trial
reported a statistically significant effect. The risk of
myocardial infarction with calcium tended to be
greater in those with dietary calcium intake above the
median but was independent of age, sex, and type of
supplement.
Limitations of the review
Our study has some limitations. We excluded studies
that compared coadministered calcium and vitamin D
supplements with placebo. The results therefore may
BMJ | ONLINE FIRST | bmj.com

not apply to coadministered calcium and vitamin D
supplements. None of the trials had cardiovascular outcomes as the primary end points, and data on cardiovascular events were not gathered in a standardised
manner. In only two of the trials were the data adjudicated by blinded trial investigators. However, unless
there was differential misclassification or misreporting
of cardiovascular events in people treated with calcium, this is unlikely to alter the results, because the
data came from blinded, placebo controlled trials.
Incomplete or no data on cardiovascular outcomes
were available for seven trials in our analysis, comprising about 15% of the total number of participants.
However, the small size of these trials and the consistency of the findings in the other eight larger trials suggest the missing data are unlikely to have substantially
changed the results.
Comparison with other studies
The current findings are consistent with trials of
patients with renal failure, in which calcium supplements were associated with an increase in mortality.13
Few comparable data are available from observational
studies of calcium supplements. One study reported a
24% increase in coronary heart disease in Finnish postmenopausal women using calcium supplements (with
or without vitamin D) compared with non-users.37
Non-fatal myocardial infarction in US men using calcium supplements compared with non-users did not
increase significantly, although the relative risk for
each fifth of supplement intake ranged between 1.02
and 1.07.38
The relations between dietary calcium intake and
cardiovascular events have also been examined. The
inverse relation between calcium intake and
page 5 of 9
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Stroke

Myocardial infarction
6

8

Hazard ratio 1.31 (95% CI 1.02 to 1.67), P=0.035

Hazard ratio 1.20 (95% CI 0.96 to 1.50), P=0.11

5
Calcium

6

4
Placebo
4

3
2

2
1
0

0

Cumulative incidence (%)

No at risk
Calcium 4097
Placebo 4054

3870
3865

3539
3588

2670
2728

1294
1320

373
388

4097
4054

Composite of myocardial infarction, stroke, or sudden death
12

Hazard ratio 1.18 (95% CI 1.00 to 1.39), P=0.057

15

8

12

6

9

4

6

2

3
1

2

3

4

3541
3589

2659
2730

1294
1312

Hazard ratio 1.09 (95% CI 0.96 to 1.23), P=0.18

0
0

5

1

2

3

4

Years
No at risk
Calcium 4097
Placebo 4054

3848
3848

3517
3566

2635
2692

1271
1292

373
386

Death
18

10

0
0

3865
3859

5
Years

360
376

4097
4054

3889
3875

3580
3618

2699
2767

1322
1340

389
399

Fig 2 | Cumulative incidence of myocardial infarction, stroke, composite of myocardial infarction, stroke, or sudden death, and
death by treatment allocation in five studies that contributed patient level data

standardised mortality ratios for ischaemic heart disease in the United Kingdom was strong.6 In two US
prospective observational studies, women in the highest fourth of calcium intake had 30-40% lower cardiovascular mortality than those in the lowest fourth,7 and
those in the highest fifth of calcium intake had a 30-40%
lower risk of ischaemic stroke than those in the lowest
fifth.8 No relation between calcium intake and ischaemic heart disease or stroke was observed in prospective
Table 4 | Baseline characteristics of participants in five studies included in patient level
analysis by treatment allocation. Values are percentages unless stated otherwise
Characteristics

Calcium group

Placebo group

74.5 (70-79)

74.6 (71-79)

Women

76.5

79.2

White ethnicity

97.2

97.7

68.4 (14.1)

67.9 (13.7)

Median (interquartile range) age (years)

Mean (SD) weight (kg)
Mean (SD) dietary calcium (mg/day)

837 (377)

831 (370)

Mean (SD) 25-hydroxyvitamin D (nmol/l)*

66.1 (28.9)

64.3 (27.5)

Current smoker

11.0

10.2

Hypertension†

28.0

28.4

Ischaemic heart disease†

8.1

7.8

Lipid disorder†

14.8

15.4

Diabetes

7.0

6.7

Proportion of women was significantly higher in placebo group because one study that only involved men had a
2:1 ratio of allocation to calcium or placebo.33 No other differences existed between groups. Medical conditions
at baseline were self reported by participants.
*Data available from four studies for 1445 participants in calcium groups and 1355 in placebo groups.
†Data available from four studies for 1480 participants in calcium groups and 1379 in placebo groups.
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studies of US men,38 39 or of Dutch civil servants.40
Thus, in contrast with the observational and interventional studies of calcium supplements, these observational studies do not show increased cardiovascular
risks with higher dietary calcium intake. These differences suggest that cardiovascular risks from high calcium intake might be restricted to use of calcium
supplements.
A body of evidence related to the current work
comes from studies comparing coadministered calcium and vitamin D supplements with placebo,
which were excluded from our meta-analysis.
Recently, the Women’s Health Initiative reported
that calcium and vitamin D had no effect on the risk
of coronary heart disease or stroke.41 The findings of
that study might differ from ours for several reasons.
The Women’s Health Initiative used low dose vitamin
D supplements, and vitamin D deficiency has been
associated with increased risk of cardiovascular
disease42 and vitamin D supplementation with
decreased mortality.17 Also, the participants differed
from those in our meta-analysis: on average they
were younger (mean age 62 v 75 years), heavier
(mean weight 76 v 68 kg; 34% in Women’s Health
Initiative v 10% of women in our meta-analysis
weighed >80 kg), had higher calcium intakes (mean
1150 v 830 mg/day), and a higher proportion were
using hormone replacement therapy (52% v <3% in
our meta-analysis). Overall, 54% were taking nonBMJ | ONLINE FIRST | bmj.com
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Study

Relative risk of myocardial
infarction (95% CI)

Weight
(%)

Study

Relative risk of
stroke (95% CI)

Weight
(%)

Baron 1999
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Reid 1993
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29

Baron 1999

6

Grant 2005 Vit D

26

Grant 2005

26

Prince 2006

13

Grant 2005 Vit D

30

Reid 2006

17

Prince 2006

20

Lappe 2007

1

Reid 2006

14

Reid 2008

1

Bonnick 2007

1

Lappe 2007

2

Total
P=0.038

Test for heterogeneity:

1.27 (1.01 to 1.59)

1

Total

I2=0% P=0.96

P=0.25

Test for heterogeneity:

1.12 (0.92 to 1.36)

I2=0% P=0.93
Study

Relative risk of myocardial infarction,
stroke, or sudden death (95% CI)

Weight
(%)

Study

Weight
(%)

Relative risk of
death (95% CI)

0.4

Baron 1999

4

Baron 1999

9

Grant 2005

43

Grant 2005

27

Grant 2005 Vit D

42

Grant 2005 Vit D

28

Prince 2006

5

Prince 2006

17

Reid 2006

Reid 2006

16

Bonnick 2007

0.2

Reid 2008

0.2

Reid 1993

2

Lappe 2007

0.2

Reid 2008

Total
P=0.26

Test for heterogeneity:

Total
P=0.13

Test for heterogeneity:
I2=0% P=0.91

5

0.5
Favours
calcium

1.12 (0.97 to 1.30)

0.8 1 1.2 1.5

2

I2=0% P=0.84
3

Favours
placebo

0.5
Favours
calcium

1.07 (0.95 to 1.19)

0.8 1 1.2 1.5

2

3

Favours
placebo

Fig 3 | Random effects models of effect of calcium supplementation on cardiovascular events and death. Full data were
available from these eight trials, but some trials do not appear in the figures because no events occurred during the trial: no
myocardial infarctions occurred in the study by Reid 199321 22 or Bonnick 2007,30 no strokes occurred in the study by Reid
2008,33 and no deaths occurred in the study by Reid 1993.21 22 Data on composite end point were not available for the study
by Bonnick 200730 or Lappe 2007.31 32 Grant 2005 is a Randomised Evaluation of Calcium or Vitamin D (RECORD) study calcium
versus placebo arms, and Grant 2005 vitamin D is a RECORD study calcium plus vitamin D versus vitamin D plus placebo arms

protocol calcium supplements at baseline (30% were
taking ≥500 mg/day), increasing to 69% at the final
visit,43 44 compared with 1.2% taking non-protocol
calcium supplements at baseline in our meta-analysis.
In the subgroups of women in the Women’s Health
Initiative who most closely approximated the participants in our analyses (age 70-79 years, body mass
index <30 kg/m2, total calcium intake <800 mg/day),
the confidence intervals of the hazard ratios for coronary heart disease with calcium and vitamin D included
the hazard ratio for myocardial infarction we observed.
It would be valuable to reanalyse the results of the
Women’s Health Initiative to assess the effects of calcium and vitamin D in non-obese women and in
women not taking non-protocol calcium supplements.
Interestingly, the only study in our analysis that
reported a relative risk of less than 1.0 for myocardial
infarction with calcium also had high non-protocol use
of calcium supplements.31 32 45
The current analyses do not deal with the mechanisms by which calcium supplements might increase the
risk of myocardial infarction, but we have reviewed
this elsewhere.46 Calcium supplements acutely
increase serum calcium levels to a modest degree.47
Serum calcium levels have been positively associated
BMJ | ONLINE FIRST | bmj.com

with an increased incidence of myocardial infarction in
large observational studies.48-50 Primary hyperparathyroidism, a condition in which serum calcium levels
are raised, has also been associated with an increased
risk of cardiovascular events and death.51 52 Ingestion
of equivalent doses of calcium from dairy products has
a much smaller effect than calcium supplements on
serum calcium levels,53 which might account for the
absence of a detrimental vascular effect of dietary calcium intake in the observational studies reviewed. Vascular calcification is an established risk factor for
cardiovascular disease,54 and the process of vascular
calcification is similar to osteogenesis.55 Because calcium supplements increase bone density it is possible
that they may also increase vascular calcification and
thereby cardiovascular events. In patients with renal
failure (both dialysis and predialysis populations) calcium supplements accelerate vascular calcification and
increase mortality.12-14 Our graphical data are consistent with the possibility that an increased risk of myocardial infarction with calcium supplements emerges
quickly, pointing to mechanisms such as increased coagulability or altered vascular flow, perhaps mediated
directly through the calcium sensing receptor or indirectly through alterations in calcitropic hormones.
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WHAT IS ALREADY KNOWN ON THIS TOPIC
Calcium supplements are commonly taken by older people for skeletal health
A randomised placebo controlled trial suggested calcium supplements might increase the
risk of myocardial infarction and cardiovascular events

WHAT THIS STUDY ADDS
A meta-analysis of trials totalling 12 000 participants found that calcium supplements
increase the risk of myocardial infarction by about 30%
Given the modest benefits of calcium supplements on bone density and fracture prevention,
a reassessment of the role of calcium supplements in the management of osteoporosis is
warranted

Calcium supplements modestly increase bone
density3 15 33 and have marginal efficacy against
fracture.2 3 In a pooled analysis of studies contributing
patient level data,15 21 22 25 28 33 the hazard ratio for fracture was 0.90 (95% confidence interval 0.80 to 1.01)
and NNT for five years to prevent one fracture was 39.
A recent meta-analysis of the effect of calcium with or
without vitamin D on fracture reported a similar NNT
for five years of 48.3 Later meta-analyses reported that
combined supplementation with calcium and vitamin D
reduced fractures, whereas vitamin D alone did not.56 57
Incorporating the results from the current analysis of
studies contributing patient level data, treatment of
1000 people with calcium for five years would cause
an additional 14 myocardial infarctions, 10 strokes,
and 13 deaths, and prevent 26 fractures.

AA is funded by a career scientist award of the chief scientist office of the
Scottish government health directorates. The Health Services Research
Unit is funded by the chief scientist office of the Scottish government
health directorates. The sponsors of the study had no role in design and
conduct of the study; collection, management, analysis, and
interpretation of the data; and preparation, review, or approval of the
manuscript. The authors are independent from the funders.
Competing interests: All authors have completed the unified competing
interest form at www.icmje.org/coi_disclosure.pdf (available on request
from the corresponding author) and declare that: (1) no author has
support from companies for the submitted work; (2) IR has received
research support from and acted as a consultant for Fonterra that might
have an interest in the submitted work in the previous 3 years; JB, IR, AA
and GM had study drugs for clinical trials of calcium supplementation
supplied by Wyeth; Mission Pharmacal; Shire Pharmaceuticals and
Nycomed; and Shire Pharmaceuticals and Nycomed, respectively, might
have an interest in the submitted work in the previous 3 years; (3) their
spouses, partners, or children have no financial relationships that may be
relevant to the submitted work; and (4) no author has non-financial
interests that may be relevant to the submitted work.
Ethical approval: Not required.
Data sharing: No additional data available.
1
2

3

4

5

6

Conclusions
In summary, randomised studies suggest that calcium
supplements without coadministered vitamin D are
associated with an increased incidence of myocardial
infarction. The vascular effects of calcium supplements, especially without vitamin D, should be studied
further. Although the magnitude of the increase in risk
is modest, the widespread use of calcium supplements
means that even a small increase in incidence of cardiovascular disease could translate into a large burden of
disease in the population. The likely adverse effect of
calcium supplements on cardiovascular events, taken
together with the possible adverse effect on incidence
of hip fracture2 58 and its modest overall efficacy in
reducing fracture (about 10% reduction in total
fractures)2 3 suggest that a reassessment of the role of
calcium supplements in the prevention and treatment
of osteoporosis is warranted.
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